PITTSBURGH – (BUSINESS WIRE) – Knopp Biosciences LLC, een particulier bedrijf van medicijnontdekking en ontwikkeling gericht op het leveren van baanbrekende behandelingen voor ontstekings en neurologische ziekten van hoge onvervulde behoefte, kondigde vandaag aan dat het management op de Piper Jaffray 30ste Annual Healthcare Conference die in New York, NY op 27-29 November wordt gehouden, zal zijn.
Michael Bozik, M.D., voorzitter en CEO van Knopp Biosciences, staat gepland om op dinsdag, 27 November bij 12:50 p.m. Oostelijke Tijd zich te presenteren.
OVER KNOPP BIOSCIENCES LLC
Knopp Biosciences is een particulier bedrijf van medicijnontdekking en ontwikkeling gericht op het leveren van baanbrekende behandelingen voor ontstekings- en neurologische ziekten van hoge onvervulde behoefte.
Knopp Biosciences to Present at the Piper Jaffray 30th Annual Healthcare Conference
PITTSBURGH–(BUSINESS WIRE)– Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 30th Annual Healthcare Conference to be held in New York, NY on November 27-29.
Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, November 27th at 12:50 p.m. Eastern Time.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit knoppbio.com.
This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.